Vaccines to combat smoking

Expert Opinion on Biological Therapy

Volumn 8, Issue 4, 2008, Pages 379-383

  Bevins, Rick A ^a   Wilkinson, Jamie L ^a   Sanderson, Sam D ^b  

^a UNIVERSITY OF NEBRASKA LINCOLN   (United States)

^b UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

Author keywords

Cigarette; Cotinine; Drug specific antibody; Immune system; Immunotherapy; Nicotine addiction; Tobacco

Indexed keywords

AMFEBUTAMONE; DRUG ANTIBODY; HAPTEN; MONOCLONAL ANTIBODY; NICOTINE VACCINE; VARENICLINE; ANTIBODY; NICOTINE; NICOTINIC AGENT; VACCINE;

ALLERGIC REACTION; COGNITION; DEMOGRAPHY; DRUG EFFICACY; DRUG RESEARCH; HUMAN; IMMUNIZATION; IMMUNOGENICITY; NICOTINE REPLACEMENT THERAPY; PERIPHERAL CIRCULATION; REVIEW; SMOKING CESSATION; SMOKING HABIT; TOBACCO DEPENDENCE; ARTICLE; BLOOD; DRUG DESIGN; IMMUNOLOGY; METHODOLOGY; SMOKING;

NICOTIANA TABACUM;

ANTIBODIES; DRUG DESIGN; HUMANS; NICOTINE; NICOTINIC AGONISTS; SMOKING; SMOKING CESSATION; VACCINES;

EID: 42149174454     PISSN: 14712598     EISSN: None     Source Type: Journal    
DOI: 10.1517/14712598.8.4.379     Document Type: Review

References (18)

1. MacKay J, Eriksen M. The Tobacco Atlas. Switzerland: World Health Organization; 2002
2. Tobacco addiction. National Institute on Drug Abuse Research Report Series. Available from: URL: www.drugabuse.gov/PDF/RRTobacco.pdf [last accessed March 6, 2008]
3. Cerny EH, Levy R, Mauel J, et al. Preclinical development of a vaccine Against Smoking'. Onkologie 2002;25:406-11
4. LeSage MG, Keyler DE, Pentel PR. Current status of immunologic approaches to treating tobacco dependence: vaccines and nicotine-specific antibodies. AAPS J 2006;8:E65-75 •• This well-written paper provides a recent and comprehensive review of the research related to nicotine vaccines, as well as important considerations for their use in humans.
5. Vocci FJ, Chiang CN. Vaccines against nicotine: how effective are they likely to be in preventing smoking? CNS Drugs 2001;15:505-14
6. Kosten T, Owens SM. Immunotherapy for the treatment of drug abuse. Pharmacol Ther 2005;108:76-85 •• This article provides a highly accessible, yet detailed and thought-provoking review of a vaccine approach to treating drug addiction more broadly.
7. Pentel PR, Keyler DE. Vaccines to treat drug addiction. In: New Generation Vaccines. 3rd edition. Levine MM, editor. New York: Dekker; 2004. p. 1057-66
8. LeSage MG, Keyler DE, Hieda Y, et al. Effects of a nicotine conjugate vaccine on the acquisition and maintenance of nicotine self-administration in rats. Psychopharmacology (Berl) 2006;184:409-16
9. Hatsukami DK, Rennard S, Jorenby D, et al. Safety and immunogenicity of a nicotine conjugate vaccine in current smokers. Clin Pharmacol Ther 2005;78:456-67 • This paper reports an early treatment study indicating that Nabi Pharmaceutical's vaccine NicVAX produced nicotine-specific antibodies and was well tolerated in human participants.
10. Maurer P, Jennings GT, Willers J, et al. A therapeutic vaccine for nicotine dependence: preclinical efficacy, and phase I safety and immunogenicity. Eur J Immunol 2005;35:2031-40 • This paper reports an early treatment study indicating that Cytos Biotechnology's vaccine NicQb induced produced nicotine-specific antibodies and was well tolerated in human participants.
11. St Clair Roberts J, Dobson J, Wood D, Settles M. Safety and immunogenicity of a human nicotine conjugate vaccine. Drug Alcohol Depend 2002;66:S148
12. Pentel PR, Malin DH. Vaccines for nicotine dependence. Targeting the drug instead of the brain. Respiration 2002;69:193-7
13. Perkins KA. Sex differences in nicotine reinforcement and reward: influences on the persistence of tobacco smoking. In: The Motivational Impact of Nicotine and its Role in Tobacco Use: The 55th Nebraska Symposium on Motivation. Bevins RA, Caggiula AR, editors. New York: Springer; In press
14. Sanderson SD, Vennerstrom JL, Cheruku SR, et al. Active immunization against nicotine with a peptide vaccine composed of a conformationally biased agonist of C5a as a molecular adjuvant. Int Immunopharmacol 2003;3:137-46
15. Oliver JL, Pashmi G, Barnett P, et al. Development of an anti-cotinine vaccine to potentiate nicotine-based smoking cessation strategies. Vaccine 2007;25:7354-62 • Along with providing preclinical evidence in support of a vaccine for the major metabolite of nicotine (cotinine), this paper prompts broader consideration of immunotherapy approaches to smoking that target more than the primary addictive constituents of tobacco.
16. Bardo MT, Green TA, Crooks PA, Dwoskin LP. Nornicotine is self-administered intravenously by rats. Psychopharmacology 1999;146:290-6
17. DiFranza JR, Savageau JA, Fletcher K, et al. Recollections and repercussions of the first inhaled cigarette. Addict Behav 2004;29:261-72
18. Pomerleau OF, Pomerleau CS, Namenek RJ. Early experiences with tobacco among women smokers, experiment-smokers, and never-smokers. Addiction 1998;93:595-9